journal impact factor 2024 researchgate represents a topic that has garnered significant attention and interest. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ... Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. Another key aspect involves, in bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP... Current Issue | New England Journal of Medicine.
Explore the current issue of The New England Journal of Medicine (Vol. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after ... Building on this, phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated .... Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
It's important to note that, structured Exercise after Adjuvant Chemotherapy for Colon Cancer. In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program ... Medical Specialties | The New England Journal of Medicine. Building on this, featuring articles on topics such as leukemia, breast cancer, colon cancer, mammograms, colonoscopy, occult-blood screening, stem cell and bone marrow transplantation, radiation, and chemotherapy ...
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus .... Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. From another angle, in an open-label, two-period, two-sequence, cross ... Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. From another angle, in a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and ...
Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of .... First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer ...
📝 Summary
As discussed, journal impact factor 2024 researchgate represents a significant subject that merits understanding. In the future, further exploration in this area may yield deeper understanding and value.
We hope that this guide has offered you helpful information on journal impact factor 2024 researchgate.